Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

Revance Therapeutics Releases Fourth Quarter And Full Year 2014 Financial Results And Reiterates 2015 Outlook - Yahoo Finance

"Revance Therapeutics", TransMTS(R) and the Revance logo are registered trademarks of Revance Therapeutics, Inc. BOTOX (R) is a registered trademark of Allergan, http://sweatingblog.info Inc. Forward-Looking Statements This press release contains forward-looking statements, including statements related to Revance Therapeutics' 2015 Financial Outlook and other financial performance, the process and timing of, and ability to complete, current and anticipated future clinical development of our product candidates, including but limited to initiation and design of clinical studies for current and future indications, related results and reporting of such results; statements about our business strategy, goals and market for our anticipated products, plans and prospects; our ability to obtain regulatory approval; potential benefits of our product candidates and our technologies; and future financial performance. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/revance-therapeutics-releases-fourth-quarter-210500437.html

Revance Appoints Dr. Philip Vickers to Its Board of Directors - Yahoo Finance

Dr. Vickers is a member of Shire's stop sweating Executive and Pipeline Committees. "Revance is honored to add a pharmaceutical executive with such significant strategic business and R&D expertise to our board," said Dan Browne, co-founder, President and Chief Executive Officer of Revance. "Phil's hands-on operating experience and insights will be great assets as we execute our clinical research and development programs to move toward regulatory approval of our novel neurotoxin product candidates, RT001 and RT002, and expand our botulinum toxin pipeline into a wide variety of therapeutic areas." "I have long admired the innovative work that Dan and his team have accomplished to advance the neurotoxin field for multiple indications. Revance is emerging as a true leader in developing new and exciting compositions and delivery technologies for botulinum toxin.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/revance-appoints-dr-philip-vickers-220000463.html

Don't be the product, buy the product!